Carna Biosciences, Inc. (4572.T)
JPY 280.0
(-1.41%)
JPY 280.0
(-1.41%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -1.11 Billion JPY | 12.04% |
| 2022 | -1.26 Billion JPY | -139.09% |
| 2021 | -531.13 Million JPY | 49.75% |
| 2020 | -1.05 Billion JPY | -208.11% |
| 2019 | 977.77 Million JPY | 185.43% |
| 2018 | -1.14 Billion JPY | -63.72% |
| 2017 | -699.06 Million JPY | -64.88% |
| 2016 | -423.97 Million JPY | -189.68% |
| 2015 | 472.78 Million JPY | 174.46% |
| 2014 | -634.94 Million JPY | -111.16% |
| 2013 | -300.7 Million JPY | 34.32% |
| 2012 | -457.84 Million JPY | -16.43% |
| 2011 | -393.23 Million JPY | 1.24% |
| 2010 | -398.18 Million JPY | -15.66% |
| 2009 | -344.27 Million JPY | -16.21% |
| 2008 | -296.26 Million JPY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -678.76 Million JPY | -63.07% |
| 2024 Q1 | -416.23 Million JPY | -590.98% |
| 2023 Q1 | -505.79 Million JPY | 2.01% |
| 2023 Q2 | -357.9 Million JPY | 29.24% |
| 2023 Q4 | 84.77 Million JPY | 125.08% |
| 2023 FY | -1.11 Billion JPY | 12.04% |
| 2023 Q3 | -338.05 Million JPY | 5.54% |
| 2022 Q2 | -313.15 Million JPY | -2242.68% |
| 2022 FY | -1.26 Billion JPY | -139.09% |
| 2022 Q4 | -516.18 Million JPY | -16.87% |
| 2022 Q1 | 14.61 Million JPY | -97.71% |
| 2022 Q3 | -441.68 Million JPY | -41.05% |
| 2021 Q4 | 637.88 Million JPY | 262.86% |
| 2021 FY | -531.13 Million JPY | 49.75% |
| 2021 Q1 | -291.21 Million JPY | 34.02% |
| 2021 Q2 | -486.12 Million JPY | -66.93% |
| 2021 Q3 | -391.67 Million JPY | 19.43% |
| 2020 Q4 | -441.38 Million JPY | -83.59% |
| 2020 Q3 | -240.41 Million JPY | -14.38% |
| 2020 Q2 | -210.19 Million JPY | -27.33% |
| 2020 Q1 | -165.07 Million JPY | 56.47% |
| 2020 FY | -1.05 Billion JPY | -208.11% |
| 2019 FY | 977.77 Million JPY | 185.43% |
| 2019 Q4 | -379.23 Million JPY | -301.77% |
| 2019 Q2 | 1.68 Billion JPY | 822.6% |
| 2019 Q1 | -233.11 Million JPY | 38.94% |
| 2019 Q3 | -94.39 Million JPY | -105.6% |
| 2018 Q2 | -247.82 Million JPY | -31.21% |
| 2018 Q3 | -326.06 Million JPY | -31.57% |
| 2018 Q1 | -188.87 Million JPY | 14.79% |
| 2018 FY | -1.14 Billion JPY | -63.72% |
| 2018 Q4 | -381.76 Million JPY | -17.08% |
| 2017 Q3 | -185.56 Million JPY | -4.14% |
| 2017 Q2 | -178.19 Million JPY | -56.79% |
| 2017 Q1 | -113.64 Million JPY | -26.91% |
| 2017 FY | -699.06 Million JPY | -64.88% |
| 2017 Q4 | -221.65 Million JPY | -19.45% |
| 2016 Q3 | -138.92 Million JPY | -71.14% |
| 2016 Q1 | -114.33 Million JPY | -2.52% |
| 2016 FY | -423.97 Million JPY | -189.68% |
| 2016 Q4 | -89.55 Million JPY | 35.54% |
| 2016 Q2 | -81.17 Million JPY | 29.0% |
| 2015 FY | 472.78 Million JPY | 174.46% |
| 2015 Q3 | -95.44 Million JPY | -116.43% |
| 2015 Q4 | -111.51 Million JPY | -16.84% |
| 2015 Q2 | 580.8 Million JPY | 487.03% |
| 2015 Q1 | 98.93 Million JPY | 144.3% |
| 2014 Q2 | -168.29 Million JPY | -54.24% |
| 2014 FY | -634.94 Million JPY | -111.16% |
| 2014 Q1 | -109.11 Million JPY | -21.26% |
| 2014 Q3 | -134.23 Million JPY | 20.24% |
| 2014 Q4 | -223.31 Million JPY | -66.37% |
| 2013 Q1 | -71.02 Million JPY | 24.03% |
| 2013 Q4 | -89.97 Million JPY | -119.13% |
| 2013 Q3 | -41.06 Million JPY | 58.37% |
| 2013 Q2 | -98.63 Million JPY | -38.87% |
| 2013 FY | -300.7 Million JPY | 34.32% |
| 2012 Q3 | -128.15 Million JPY | -5.78% |
| 2012 Q4 | -93.49 Million JPY | 27.04% |
| 2012 FY | -457.84 Million JPY | -16.43% |
| 2012 Q2 | -121.15 Million JPY | -5.31% |
| 2012 Q1 | -115.04 Million JPY | -8.63% |
| 2011 Q1 | -65.42 Million JPY | 33.28% |
| 2011 Q3 | -99.8 Million JPY | 18.27% |
| 2011 Q4 | -105.9 Million JPY | -6.12% |
| 2011 FY | -393.23 Million JPY | 1.24% |
| 2011 Q2 | -122.11 Million JPY | -86.65% |
| 2010 FY | -398.18 Million JPY | -15.66% |
| 2010 Q1 | -93.33 Million JPY | 18.51% |
| 2010 Q3 | -118.28 Million JPY | -33.63% |
| 2010 Q4 | -98.05 Million JPY | 17.11% |
| 2010 Q2 | -88.51 Million JPY | 5.16% |
| 2009 FY | -344.27 Million JPY | -16.21% |
| 2009 Q1 | -83.67 Million JPY | 0.0% |
| 2009 Q2 | -78.94 Million JPY | 5.64% |
| 2009 Q3 | -67.12 Million JPY | 14.98% |
| 2009 Q4 | -114.53 Million JPY | -70.64% |
| 2008 FY | -296.26 Million JPY | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 596.82 Million JPY | 287.154% |
| PRISM BioLab Co.,LTD | -496.86 Million JPY | -124.804% |
| GNI Group Ltd. | 13.1 Billion JPY | 108.521% |
| Linical Co., Ltd. | 725.72 Million JPY | 253.912% |
| Trans Genic Inc. | 89.43 Million JPY | 1348.913% |
| MEDINET Co., Ltd. | -1.42 Billion JPY | 21.668% |
| Soiken Holdings Inc. | -610 Million JPY | -83.109% |
| Cytori Cell Research Institute, Inc. | -772.74 Million JPY | -44.547% |
| AnGes, Inc. | -11.96 Billion JPY | 90.667% |
| OncoTherapy Science, Inc. | -1.12 Billion JPY | 0.341% |
| Nxera Pharma Co., Ltd. | -9.52 Billion JPY | 88.274% |
| Immuno-Biological Laboratories Co., Ltd. | 104.29 Million JPY | 1170.938% |
| NanoCarrier Co., Ltd. | -864.41 Million JPY | -29.218% |
| CanBas Co., Ltd. | -1.26 Billion JPY | 11.491% |
| D. Western Therapeutics Institute, Inc. | -798.55 Million JPY | -39.874% |
| RaQualia Pharma Inc. | -337.36 Million JPY | -231.089% |
| Chiome Bioscience Inc. | -1.2 Billion JPY | 7.318% |
| Kidswell Bio Corporation | -1.33 Billion JPY | 16.369% |
| PeptiDream Inc. | 6.77 Billion JPY | 116.492% |
| Oncolys BioPharma Inc. | -1.92 Billion JPY | 42.125% |
| Ribomic Inc. | -1.11 Billion JPY | -0.07% |
| SanBio Company Limited | -4.53 Billion JPY | 75.392% |
| Healios K.K. | -3.37 Billion JPY | 66.944% |
| BrightPath Biotherapeutics Co., Ltd. | -1.15 Billion JPY | 3.299% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -1.39 Billion JPY | 19.844% |
| Delta-Fly Pharma, Inc. | -1.4 Billion JPY | 20.386% |
| StemRIM | -2.07 Billion JPY | 46.196% |
| CellSource Co., Ltd. | 1.22 Billion JPY | 191.443% |
| FunPep Company Limited | -994 Million JPY | -12.372% |
| Kringle Pharma, Inc. | -888.76 Million JPY | -25.678% |
| Stella Pharma Corporation | -760.3 Million JPY | -46.913% |
| TMS Co., Ltd. | -943.25 Million JPY | -18.418% |
| Noile-Immune Biotech Inc. | -775.39 Million JPY | -44.054% |
| Cuorips Inc. | -588.48 Million JPY | -89.805% |
| K Pharma,Inc. | 366.05 Million JPY | 405.138% |
| Takara Bio Inc. | 3 Billion JPY | 137.195% |
| ReproCELL Incorporated | -409.29 Million JPY | -172.904% |
| PhoenixBio Co., Ltd. | 11.06 Million JPY | 10196.52% |
| StemCell Institute Inc. | 413.75 Million JPY | 369.959% |
| Japan Tissue Engineering Co., Ltd. | 144.5 Million JPY | 872.958% |
| CellSeed Inc. | -697.77 Million JPY | -60.077% |